Literature DB >> 22137884

Bacterial host interactions in cystic fibrosis.

Máire Callaghan1, Siobhán McClean.   

Abstract

Chronic infection is a hallmark of cystic fibrosis (CF) and the main contributor to morbidity. Microbial infection in CF is complex, due to the number of different species that colonise the CF lung. Their colonisation is facilitated by a host response that is impaired or compromised by highly viscous mucous, zones of hypoxia and the lack of the cystic fibrosis transmembrane regulator (CFTR). Successful dominant CF pathogens combine an effective arsenal to establish infection and counter-attack the host response, together with an ability to adapt readily to an unfavourable environment. Hypermutability is common among CF pathogens facilitating adaptation and as the host response persists, progressive destruction of the normal architecture of lung tissue ensues with catastrophic consequences for the host.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22137884     DOI: 10.1016/j.mib.2011.11.001

Source DB:  PubMed          Journal:  Curr Opin Microbiol        ISSN: 1369-5274            Impact factor:   7.934


  23 in total

1.  Linocin and OmpW Are Involved in Attachment of the Cystic Fibrosis-Associated Pathogen Burkholderia cepacia Complex to Lung Epithelial Cells and Protect Mice against Infection.

Authors:  Siobhán McClean; Marc E Healy; Cassandra Collins; Stephen Carberry; Luke O'Shaughnessy; Ruth Dennehy; Áine Adams; Helen Kennelly; Jennifer M Corbett; Fiona Carty; Laura A Cahill; Máire Callaghan; Karen English; Bernard P Mahon; Sean Doyle; Minu Shinoy
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

2.  Differential In Vitro and In Vivo Toxicities of Antimicrobial Peptide Prodrugs for Potential Use in Cystic Fibrosis.

Authors:  Éanna Forde; André Schütte; Emer Reeves; Catherine Greene; Hilary Humphreys; Marcus Mall; Deirdre Fitzgerald-Hughes; Marc Devocelle
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 3.  Cystic fibrosis: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases.

Authors:  Jessica E Pittman; Garry Cutting; Stephanie D Davis; Thomas Ferkol; Richard Boucher
Journal:  Ann Am Thorac Soc       Date:  2014-04

4.  The virtues of oxygenation: low tissue oxygen adversely affects the killing of Leishmania.

Authors:  Lopa M Das; Kurt Q Lu
Journal:  J Invest Dermatol       Date:  2014-09       Impact factor: 8.551

5.  Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors.

Authors:  Mai Alhajlan; Moayad Alhariri; Abdelwahab Omri
Journal:  Antimicrob Agents Chemother       Date:  2013-04-01       Impact factor: 5.191

6.  Developing an international Pseudomonas aeruginosa reference panel.

Authors:  Anthony De Soyza; Amanda J Hall; Eshwar Mahenthiralingam; Pavel Drevinek; Wieslaw Kaca; Zuzanna Drulis-Kawa; Stoyanka R Stoitsova; Veronika Toth; Tom Coenye; James E A Zlosnik; Jane L Burns; Isabel Sá-Correia; Daniel De Vos; Jean-Paul Pirnay; Timothy J Kidd; David Reid; Jim Manos; Jens Klockgether; Lutz Wiehlmann; Burkhard Tümmler; Siobhán McClean; Craig Winstanley
Journal:  Microbiologyopen       Date:  2013-11-11       Impact factor: 3.139

Review 7.  The Evolution of Cystic Fibrosis Care.

Authors:  Jessica E Pittman; Thomas W Ferkol
Journal:  Chest       Date:  2015-08       Impact factor: 9.410

Review 8.  Host defenses against bacterial lower respiratory tract infection.

Authors:  Taylor Eddens; Jay K Kolls
Journal:  Curr Opin Immunol       Date:  2012-07-25       Impact factor: 7.486

Review 9.  Bacterial siderophores in community and host interactions.

Authors:  Jos Kramer; Özhan Özkaya; Rolf Kümmerli
Journal:  Nat Rev Microbiol       Date:  2019-11-20       Impact factor: 60.633

10.  Microbial Interactions in the Cystic Fibrosis Airway.

Authors:  Ann M Granchelli; Frederick R Adler; Ruth H Keogh; Christiana Kartsonaki; David R Cox; Theodore G Liou
Journal:  J Clin Microbiol       Date:  2018-07-26       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.